Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Down 79.8% in June

Bavarian Nordic (OTCMKTS:BVNRY) was the target of a large drop in short interest during the month of June. As of June 15th, there was short interest totaling 2,985 shares, a drop of 79.8% from the May 31st total of 14,745 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 4,713 shares, the short-interest ratio is presently 0.6 days.

Bavarian Nordic Price Performance

BVNRY opened at $9.05 on Friday. The business has a fifty day simple moving average of $9.67 and a 200 day simple moving average of $9.89. Bavarian Nordic has a 1 year low of $8.67 and a 1 year high of $13.00. The company has a market capitalization of $2.15 billion, a PE ratio of 11.91 and a beta of 1.19.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $0.01 earnings per share for the quarter. Bavarian Nordic had a return on equity of 9.32% and a net margin of 19.74%.The firm had revenue of $165.70 million for the quarter.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.